An observational study in ATTR Amyloidosis With Cardiomyopathy, ATTR-CM and ATTR Amyloidosis Wild Type, sponsored by Medical University of Vienna. Recruiting at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.
Sponsored by Medical University of Vienna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Mitral Valve Insufficiency with a site in Italy — 20 open to participants now, 28 under way, none of them phase 3. Mitral Valve Insufficiency · Italy.
Among the 63 studies in Mitral Valve Insufficiency with a site in Italy, this one is the 9th largest by planned enrollment of the 33 observational ones that give a count, is one of 6 that started in 2025, is one of 33 observational ones, reaches primary completion later than 10 of the 27 other live ones, and was the 58th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →20 of the 63 studies in Mitral Valve Insufficiency with a site in Italy are open now. Recruiting first, the newest first:
Centro Cardiologico Monzino · Sites in Italy
Ages 18+
ASL Città di Torino · Sites in Italy, Belgium
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Fundación para la Investigación Biosanitaria del Principado de Asturias · Sites in Italy, Israel, Netherlands and 1 more country
Ages 18–99
Medical University of Vienna · Sites in Italy, Austria, Germany
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 6 started in 2025.
This study's planned enrollment of 600 is above the median of 159 across 170 observational studies indexed under Mitral Valve Insufficiency.
Median enrollment 95 across the 30 interventional studies, 200 across the 33 observational. Of the 24 that completed or were terminated, 7 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 63 have an industry lead sponsor. The 10 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 4 studies filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
5 of the studies in Mitral Valve Insufficiency with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07632794Mi ChenArtificial Intelligence Assisting Transcatheter Mitral Edge-to-Edge Repair | 2026-12-31 |
| NCT03339115Cardiovalve Ltd.AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System | 2026-12-31 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT04898335LMU KlinikumTendyne European Experience Registry | 2026-12-31 |
| NCT06282042Fundación para la Investigación Biosanitaria del Principado de AsturiasEarly Transcatheter Mitral Valve Repair After Myocardial Infarction | 2027-06-16 |
Add all 5 to your calendar (.ics) → With an account.
Among the 63 studies in Mitral Valve Insufficiency with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral (MR) and tricuspid regurgitation (TR) in patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). The study further aims to develop and implement new grading standards for the quantitative assessment of regurgitation severity, tailored to the distinct hemodynamic profile of ATTR-CM. This approach seeks to address the limitations of current regurgitation severity classifications, which do not adequately reflect the unique pathophysiology of a restrictive phenotype as seen in ATTR-CM.
This observational study will include patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) from international specialized cardiac amyloidosis referral centers. The study population will encompass both wild-type and hereditary ATTR-CM patients, ensuring representation of diverse disease phenotypes. Data collection will be standardized across centers, with echocardiographic assessments performed in accordance with the dedicated study protocol. The inclusion of multiple international centers will enhance the generalizability of findings across different healthcare systems and patient populations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All-cause mortality
Assessment of all-cause mortality in patients with ATTR-CM, stratified by baseline quantitative and semiquantitative measures of mitral and tricuspid regurgitation severity
Time frame: up to 60 months
Cardiovscular mortality
Time frame: up to 60 months
Heart Failure Hospitalization
Time to first heart failure hospitalization Rate of heart failure hospitalizations
Time frame: up to 60 months
Progression of Atrioventricular Regurgitation
Change in mitral and tricuspid regurgitation severity over time and its impact on clinical outcomes.
Time frame: At 12 and 24 months follow-up
Plan to share: Undecided
Started Jan 2025 (actual). Primary completion is estimated for Dec 2025, 11 months after the start.
Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 11 months is below that.
Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →